Tango Therapeutics’ Adam Crystal sells 27,000 shares

At Tango Therapeutics, Inc. (TNGX), President, R&D Adam Crystal exercised options for 27,000 shares of common stock at an exercise price of $5.20 per share on October 1, 2026, and reported 233,040 stock options following the transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

At Tango Therapeutics, Inc. (TNGX), President, R&D Adam Crystal exercised options for 27,000 shares of common stock at an exercise price of $5.20 per share on October 1, 2026, and reported 233,040 stock options following the transaction. He also sold 26,400 shares at a weighted average of $24.4547 per share and 600 shares at a weighted average of $25.32 per share. The transactions were made under a Rule 10b5-1 trading plan adopted October 27, 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 27,000 shares ($520K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Crystal Adam

Role President, R&D

Sold 27,000 shs ($661K)

Approx. gross sale proceeds $661K

Approx. exercise cost $140K

Approx. pre-tax spread $520K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) ^{F1, F4}	27,000	$0.00	$0.00
Exercise	Common Stock ^F1	27,000	$5.20	$140K
Sale	Common Stock ^{F1, F2}	26,400	$24.4547	$646K
Sale	Common Stock ^{F1, F3}	600	$25.32	$15K

Holdings After Transaction: Stock Option (Right to Buy) — 233,040 contracts (Direct); Common Stock — 115,743 shares (Direct)

Footnotes (4)

F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F4. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 27,000 shares Exercise price: $5.20 per share Stock options following transaction: 233,040 options +4 more

7 metrics

Options exercised 27,000 shares October 1, 2026

Exercise price $5.20 per share Options exercised October 1, 2026

Stock options following transaction 233,040 options Following the October 1, 2026 transaction

Shares sold 26,400 shares October 1, 2026 sale; weighted average price $24.4547 per share

Weighted average sale price $24.4547 per share 26,400-share sale on October 1, 2026

Shares sold 600 shares October 1, 2026 sale; weighted average price $25.32 per share

Weighted average sale price $25.32 per share 600-share sale on October 1, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average sales price per share, vest and become exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

vest and become exercisable financial

"shall vest and become exercisable over a four-year period"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TNGX shares did Adam Crystal sell, and at what prices?

Tango Therapeutics, Inc. President, R&D Adam Crystal sold 26,400 shares at a weighted average of $24.4547 per share and 600 shares at a weighted average of $25.32 per share on October 1, 2026. Those sales were made under a Rule 10b5-1 trading plan adopted October 27, 2025. The respective sale-price ranges were $23.96 to $24.95 and $25.04 to $25.41 per share.

What was the vesting schedule for Adam Crystal's TNGX options?

The stock option was to vest and become exercisable over a four-year period, with 25% on February 27, 2024, and the remaining option shares vesting in 36 equal monthly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/05/2026 - 05:37 PM Accepted by SEC EDGAR 10/05/2026 - 05:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last)

(First)

(Middle)

C/O TANGO THERAPEUTICS, INC.

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON

MASSACHUSETTS

02215

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M⁽¹⁾		27,000	A	$5.2	142,743	D
Common Stock	10/01/2026		S⁽¹⁾		26,400	D	$24.4547⁽²⁾	116,343	D
Common Stock	10/01/2026		S⁽¹⁾		600	D	$25.32⁽³⁾	115,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$5.2	10/01/2026		M⁽¹⁾			27,000	⁽⁴⁾	03/01/2033	Common Stock	27,000	$0	233,040	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

2. Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

3. Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

4. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

	/s/ Julie Fogarty, as attorney-in-fact	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR